©2024 Stanford Medicine
SPEARHEAD-3 Pediatric Study
Not Recruiting
Trial ID: NCT05642455
Purpose
This is a pediatric basket study to investigate the safety and efficacy of afamitresgene
autoleucel in HLA-A*02 eligible and MAGE-A4 positive subjects aged 2-21 years of age with
advanced cancers
Official Title
A Phase 1/2 Open Label, Basket Study to Assess the Safety, Tolerability and Anti-Tumor Activity of Afamitresgene Autoleucel in Pediatric Subjects With MAGE-A4 Positive Tumors
Stanford Investigator(s)
Eligibility
Inclusion Criteria:
- Age 2-21 years
- Body weight ≥ 10 kg
- Subject has histologically confirmed diagnosis of any one of the following cancers:
(A) Synovial Sarcoma, (B) MPNST, (C) Neuroblastoma, or (D) Osteosarcoma
- Must have previously received a systemic chemotherapy
- Measurable disease according to RECIST v1.1 (or INCR, 2017 Neuroblastoma only).
- HLA-A*02 positive
- Tumor shows MAGE-A4 expression confirmed by central laboratory.
- Performance Status: ECOG 0-1 or Lansky Score ≥ 80
Exclusion Criteria:
- HLA-A*02:05 in either allele; or any A*02 having same protein sequence as HLA-A*02:05
- History of allergic reactions attributed to compounds of similar chemical or biologic
composition to fludarabine, cyclophosphamide.
- History of autoimmune or immune mediated disease
- Known central nervous system (CNS) metastases.
- Other prior malignancy that is not considered by the Investigator to be in complete
remission
- Clinically significant cardiovascular disease
- Active infection with human immunodeficiency virus, hepatitis B virus, hepatitis C
virus, or human T cell leukemia virus
- Pregnant or breastfeeding
Intervention(s):
genetic: Afamitresgene autoleucel
Not Recruiting
Contact Information
Stanford University
School of Medicine
300 Pasteur Drive
Stanford,
CA
94305